SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

30 May 2024 Evaluate
A decent increase of about 47.14% in the sales to Rs. 2251.96 millions was observed for the quarter ended March 2024. The sales figure stood at Rs. 1530.45 millions during the year-ago period.Handsome Net Profit growth of 85.26% reported above the corresponding previous quarter figure of Rs. 329.94 millions to Rs. 178.10 millions.Operating profit for the quarter ended March 2024 rose to 460.99 millions as compared to 270.12 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 2251.96 1530.45 47.14 8532.73 6552.04 30.23 8532.73 6552.04 30.23
Other Income 121.94 43.03 183.38 620.73 604.82 2.63 620.73 604.82 2.63
PBIDT 460.99 270.12 70.66 2020.08 1523.85 32.56 2020.08 1523.85 32.56
Interest 2.28 6.58 -65.35 9.88 36.13 -72.65 9.88 36.13 -72.65
PBDT 458.71 263.54 74.06 2010.20 1487.72 35.12 2010.20 1487.72 35.12
Depreciation 74.72 35.09 112.94 291.28 167.37 74.03 291.28 167.37 74.03
PBT 383.99 228.45 68.08 1718.92 1320.35 30.19 1718.92 1320.35 30.19
TAX 54.05 50.35 7.35 381.34 291.69 30.73 381.34 291.69 30.73
Deferred Tax -31.08 -4.21 638.24 6.78 -1.71 -496.49 6.78 -1.71 -496.49
PAT 329.94 178.10 85.26 1337.58 1028.66 30.03 1337.58 1028.66 30.03
Equity 453.16 453.16 0.00 453.16 45316.00 -99.00 453.16 45316.00 -99.00
PBIDTM(%) 20.47 17.65 15.98 23.67 23.26 1.79 23.67 23.26 1.79

Marksans Pharma Share Price

179.55 -0.95 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×